The effectiveness of this massive resale shelf creates a persistent overhang. Traders should expect selling pressure as the selling shareholders unwind positions. Monitor for any takedown notices or Form 4 filings from Oramed and Creative Value Capital. The going-concern risk amplifies the bearish case.
Price Chart
Executive Summary
Lifeward Ltd.'s S-3 shelf registration (File No. 333-297919) became effective on August 10, 2026. This allows the company to sell up to 7,256,474 ordinary shares held by selling shareholders Oramed Pharmaceuticals and Creative Value Capital LP, representing approximately 261% of current shares outstanding. The company receives no proceeds from this resale shelf, and the massive potential overhang combined with the auditor's going-concern doubt creates a bearish overhang on the stock.
Key Facts
- Shelf registration 333-297919 declared effective on August 10, 2026.
- Covers 7,256,474 ordinary shares for resale by Oramed Pharmaceuticals and Creative Value Capital LP.
- Shares represent approximately 261% of current shares outstanding.
- Company receives no proceeds from the offering.
- Auditor has expressed substantial doubt about going concern.
Financial Impact
Potential dilution overhang of ~261% of current shares outstanding; no proceeds to company.
Risk Factors
- Massive dilution overhang from selling shareholders.
- Going-concern doubt from auditor.
- No proceeds to company — pure secondary selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002600 |
| Document: 9999999995-26-002600-index.html | 9999999995-26-002600 |
| Document: 9999999995-26-002600.txt | 9999999995-26-002600 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $7.45 $7.11 | ▼ −4.56% | ▼ −2.57% | $5.85 (−21.48%) |
Aug 14, 2026 7w ago | Press Release | $7.45 $7.11 | ▲ +4.56% | ▲ +2.57% | $5.85 (+21.48%) |
Aug 11, 2026 7w ago | EFFECT | $7.57 $7.40 | ▲ +2.18% | ▲ +1.12% | $5.85 (+22.67%) |
Aug 7, 2026 8w ago | Press Release | $7.69 $6.98 | ▼ −9.17% | ▼ −8.78% | $5.85 (−23.88%) |
May 19, 2026 19w ago | 8-K | $6.40 $6.98 | ▲ +9.06% | ▲ +8.08% | $5.85 (−8.59%) |
May 15, 2026 20w ago | 8-K | $6.70 $6.96 | ▼ −3.81% | ▼ −1.69% | $5.85 (+12.69%) |
May 15, 2026 20w ago | Press Release | $6.70 $6.96 | ▼ −3.81% | ▼ −1.69% | $5.85 (+12.69%) |
May 13, 2026 20w ago | EFFECT | $6.63 $6.80 | ▼ −2.56% | ▼ −3.18% | $5.85 (+11.76%) |
May 11, 2026 20w ago | Press Release | $6.40 $6.98 | ▲ +9.09% | ▲ +9.40% | $5.85 (−8.59%) |
Apr 27, 2026 22w ago | S-3 | $7.09 $6.98 | ▲ +1.55% | ▲ +7.02% | $5.85 (+17.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access